InspireMD Inc (NSPR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, InspireMD Inc (NSPR) has a cash flow conversion efficiency ratio of -0.265x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.89 Million) by net assets ($41.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see InspireMD Inc (NSPR) total market value for the company's overall valuation and market capitalisation.
InspireMD Inc - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how InspireMD Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
InspireMD Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InspireMD Inc ranked by their cash flow conversion efficiency. See InspireMD Inc (NSPR) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
XTI Aerospace, Inc.
NASDAQ:XTIA
|
0.767x |
|
Baan Rock Garden Public Company Limited
BK:BROCK
|
0.001x |
|
Wolford Aktiengesellschaft
VI:WOL
|
0.044x |
|
Killi Resources Ltd
AU:KLI
|
-0.250x |
|
Sunfar Computer Co Ltd
TWO:6154
|
-0.006x |
|
Wooshin System
KO:017370
|
-0.050x |
|
DPS Resources Bhd
KLSE:7198
|
-0.015x |
|
HC Group Inc
STU:HCI
|
0.125x |
Annual Cash Flow Conversion Efficiency for InspireMD Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of InspireMD Inc from 2008 to 2025. View NSPR stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $55.20 Million | $-35.10 Million | -0.636x | -4.94% |
| 2024-12-31 | $36.09 Million | $-21.87 Million | -0.606x | -46.17% |
| 2023-12-31 | $39.50 Million | $-16.38 Million | -0.415x | +53.61% |
| 2022-12-31 | $17.39 Million | $-15.54 Million | -0.894x | -126.82% |
| 2021-12-31 | $33.53 Million | $-13.21 Million | -0.394x | +47.23% |
| 2020-12-31 | $12.16 Million | $-9.08 Million | -0.747x | +59.03% |
| 2019-12-31 | $5.38 Million | $-9.81 Million | -1.822x | -109.96% |
| 2018-12-31 | $8.76 Million | $-7.61 Million | -0.868x | +70.89% |
| 2017-12-31 | $2.73 Million | $-8.13 Million | -2.982x | -60.92% |
| 2016-12-31 | $4.04 Million | $-7.50 Million | -1.853x | -147.07% |
| 2015-12-31 | $-2.95 Million | $-11.60 Million | 3.936x | -43.34% |
| 2014-12-31 | $-2.79 Million | $-19.36 Million | 6.947x | +465.44% |
| 2013-12-31 | $5.42 Million | $-10.30 Million | -1.901x | -19.34% |
| 2012-12-31 | $5.39 Million | $-8.58 Million | -1.593x | 0.00% |
| 2011-12-31 | $5.39 Million | $-8.58 Million | -1.593x | -119.31% |
| 2010-12-31 | $-2.30K | $-18.98K | 8.249x | 0.00% |
| 2009-12-31 | $-2.30K | $-18.98K | 8.249x | +1774.80% |
| 2008-12-31 | $1.68K | $-825.00 | -0.493x | -- |
About InspireMD Inc
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard c… Read more